Group launches seven-figure ad buy boosting vulnerable Democrats on drug prices

Group launches seven-figure ad buy boosting vulnerable Democrats on drug prices
© iStock

A Democratic group is launching $2 million in new digital ads highlighting vulnerable House Democrats’ efforts to lower drug prices. 

The ads from the group Protect Our Care illustrate how Democrats are seeking to keep their momentum going on health care after they focused on the issue in winning back the House last year.

The ad buy shows that even as the impeachment inquiry into President TrumpDonald John TrumpUSPS warns Pennsylvania mail-in ballots may not be delivered in time to be counted Michael Cohen book accuses Trump of corruption, fraud Trump requests mail-in ballot for Florida congressional primary MORE gains focus, Democrats are still trying to focus on kitchen-table issues like lowering drug prices. 

The new spending will bring the ads to 10 new districts of House freshmen, on top of the 10 districts that were part of an earlier $2 million buy in September focused on pre-existing conditions. 

“Rep. Elissa SlotkinElissa SlotkinPaul Junge wins Michigan GOP primary to challenge Elissa Slotkin Overnight Defense: US formally rejects Beijing's South China Sea claims | House set to consider defense policy bill next week | 57 injured as firefighters battle warship blaze House Democrat warns about 'inaccurate' polls: Trump voters 'fundamentally undercounted' MORE is standing up to big drug companies,” the narrator in the ad for Slotkin, a Michigan Democrat, states. “She’s fighting to give Medicare the power to negotiate with drug companies for lower prices, reducing your costs by as much as 55 percent.”

“Thank her for leading the fight to lower your drug prices,” it adds.

The 10 new districts in the campaign are those of Democratic Reps. Angie Craig (Minn.), Sharice DavidsSharice DavidsAmanda Adkins wins GOP primary to challenge Rep. Sharice Davids Democrats go big on diversity with new House recruits The Hill's Coronavirus Report: INOVIO R&D Chief Kate Broderick 'completely confident' world will develop a safe and effective COVID-19 vaccine; GOP boxed in on virus negotiations MORE (Kan.), Antonio DelgadoAntonio Ramon DelgadoDemocrats go big on diversity with new House recruits OVERNIGHT ENERGY: 20 states sue over Trump rule limiting states from blocking pipeline projects | House Democrats add 'forever chemicals' provisions to defense bill after spiking big amendment | Lawmakers seek extension for tribes to spend stimulus money House Democrats add some 'forever chemicals' provisions to defense bill after spiking major amendment MORE (N.Y.), Lizzie Fletcher (Texas), Jared Golden (Maine), Susie LeeSuzanne (Susie) Kelley LeeMORE (Nev.), Elaine LuriaElaine Goodman LuriaHouse panel votes against curtailing Insurrection Act powers after heated debate Republican Scott Taylor wins Virginia primary, to face Elaine Luria in rematch National Retail Federation hosts virtual 'store tours' for lawmakers amid coronavirus MORE (Va.), Lucy McBathLucia (Lucy) Kay McBathRepublicans uncomfortably playing defense The Hill's Campaign Report: Even the Post Office is political now | Primary action tonight | Super PACS at war NRCC poll finds McBath ahead of Handel in Georgia MORE (Ga.), Chris PappasChristopher (Chris) Charles PappasDemocrats demand Esper explicitly ban Confederate flag and allow Pride, Native Nations flags Trade groups make lobbying push to be included in small business loan program Expanding tax credit for businesses retaining workers gains bipartisan support MORE (N.H.) and Susan WildSusan WildThe Hill's Morning Report - Presented by Facebook - Trump, GOP on defense as nationwide protests continue Republican Lisa Scheller wins primary to take on Pennsylvania Rep. Susan Wild Key races to watch in Tuesday's primaries MORE (Pa.), all of whom face potentially tough reelection races next year. 

House Democrats are planning to vote next month on their signature legislation to lower drug prices, known as H.R. 3, which would empower the secretary of Health and Human Services to negotiate lower prices for up to 250 drugs per year. 

Speaker Nancy PelosiNancy PelosiSusan Collins asks postmaster general to address delays of 'critically needed mail' Trump says he'd sign bill funding USPS but won't seek changes to help mail voting On The Money: Senate leaves until September without coronavirus relief agreement | Weekly jobless claims fall below 1 million for first time since March | Trump says no Post Office funding means Democrats 'can't have universal mail-in voting' MORE’s (D-Calif.) office has expressed hope that Trump would back the legislation, given his support for Medicare negotiating drug prices during the 2016 campaign. But Trump backed off that support in office, and the White House has recently criticized Pelosi’s bill, in favor of a somewhat more modest bipartisan measure to lower drug prices in the Senate. 

Republicans warn Pelosi’s bill would hinder the development of new cures. 

“We don’t see that happening,” Protect Our Care Chair Leslie Dach said of GOP support for the bill.

“Every statement from the president is that he opposes it,” he added. 

Campaigning on the issue could still prove effective for Democrats given the priority the public places on lowering drug prices. 

Dach said the ads are to “be sure [House Democrats] get thanked and be sure their constituents know they’re doing it.”